ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 105 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.03 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,813,484 | -21.2% | 90,403 | +10.8% | 0.00% | 0.0% |
| Q2 2023 | $2,302,500 | +112.1% | 81,620 | +29.3% | 0.00% | 0.0% |
| Q1 2023 | $1,085,647 | -9.1% | 63,119 | +0.1% | 0.00% | 0.0% |
| Q4 2022 | $1,194,077 | -6.9% | 63,086 | +5.9% | 0.00% | 0.0% |
| Q3 2022 | $1,282,158 | -21.8% | 59,560 | -0.5% | 0.00% | 0.0% |
| Q2 2022 | $1,639,929 | -48.6% | 59,862 | -14.3% | 0.00% | -50.0% |
| Q1 2022 | $3,190,525 | +108.5% | 69,813 | +279.0% | 0.00% | +100.0% |
| Q4 2021 | $1,530,000 | +25.8% | 18,421 | +1.0% | 0.00% | 0.0% |
| Q3 2021 | $1,216,000 | +23.1% | 18,240 | -1.8% | 0.00% | 0.0% |
| Q2 2021 | $988,000 | +40.9% | 18,565 | +14.8% | 0.00% | 0.0% |
| Q1 2021 | $701,000 | -20.4% | 16,166 | -4.7% | 0.00% | 0.0% |
| Q4 2020 | $881,000 | +325.6% | 16,962 | +167.7% | 0.00% | – |
| Q3 2020 | $207,000 | -23.3% | 6,337 | +6.8% | 0.00% | – |
| Q2 2020 | $270,000 | – | 5,935 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
| Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
| Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
| Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
| Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
| Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
| Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
| Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
| Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |